

FIG. 1




FIG. 2

தமிழ் தெவிடப் பதில் தமிழ்நாட்டின் தெவிடப் பதில்




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7






FIG. 8








FIG. II




FIG. 12




FIG. 13

Pharmacokinetic Data for Oral Progesterone Formulations Dosed to Dogs (40mg)

AUC is calculated by trapezoidal rule from time zero to the last blood sampling point (12h).

The relative bioavailability is the ratio of AUC for liquid formulations to that for laqueus drug-layer formulation.

Components	Formulation #				
	1	2	3	4	5
Progesterone	60	4	4	4	4
Mannitol	21				
Ac-di-sol	10				
Myji 52-s	5				
HPMC E-5	3				
Mg stearate	1				
Cremophor EL				48	48
Myvacet 9-45				96	96
Olive oil					48

41

**Pharmacokinetic Data for Emulsion Progesterone Formulation and
Nonemulsion Push-Pill Drug-Layer Formulation (300mg dose)**

Formulation #	T _{max} (h)			C _{max} (ng/ml)			AUC (ng/ml) [•] h)			Relative BA (%) Average (s.d)		
	Dog 1	2	3	Avg	Dog 1	2	3	Avg (s.d)	Dog 1	2	3	Avg (s.d)
Nonemulsion	2	1	1	1.33	489	778	649	639(145)	1101	1715	898	1238(425)
Emulsion	1	1	1	1	4800	3420	5180	4467(926)	7715	4708	7418	6614(1657)

AUC is calculated by trapezoidal rule from time zero to the last blood sampling point (12h).
The relative bioavailability is the ratio of AUC for liquid formulations to that for MPA-22 drug-layer formulation.

Formulation Composition (wt%)		
Components	Nonemulsion Drug-Layer	Emulsion Oral Formulation
Progesterone	60	50
Mannitol	21	
Ac-di-sol	10	
Myji 52-s	5	12.5
HPMC E-5	3	
Mg stearate	1	
Cremophor EL		25.0
Myvacet 9-45		12.5

FIG. 15